Vaccines

Phase I trial of C. difficile vaccine in elderly subjects begins

Published in Vaccine Weekly, December 28th, 2005

Acambis plc (ACM, ACAM) has started a phase I clinical trial of its investigational vaccine against Clostridium difficile (C. difficile) in healthy elderly subjects.

This follows an initial phase I safety and immunogenicity trial in healthy young adults that commenced in July and is the next step in the company's clinical development plan for this vaccine candidate.

C. difficile infection, which is characterized by diarrhea and colitis, is one of the most common hospital-acquired infections around the world. A hyper-virulent, hyper-toxigenic strain of C. difficile has recently emerged and is believed to be responsible for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry